Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

US surgeons perform first pig-to-human kidney transplant

Published 03/21/2024, 10:29 AM
Updated 03/22/2024, 05:35 AM
© Reuters. People walk past a sign at the entrance to Massachusetts General Hospital, where a patient is being treated for monkeypox, in Boston, Massachusetts, U.S., May 19, 2022. REUTERS/Brian Snyder

By Nancy Lapid

(Reuters) -A 62-year-man with end-stage renal disease has become the first human to receive a new kidney from a genetically modified pig, doctors from Massachusetts General Hospital in Boston announced on Thursday.

The four-hour surgery, performed on March 16, “marks a major milestone in the quest to provide more readily available organs to patients,” the hospital said in a statement.

The patient, Richard Slayman of Weymouth, Massachusetts, is recovering well and expected to be discharged soon, the hospital said.

Experts are keenly interested in long-term results of the groundbreaking animal-to-human transplant, said Dr. Jim Kim, director of kidney and pancreas transplantation with USC Transplant Institute in Los Angeles.

Slayman had received a transplant of a human kidney at the same hospital in 2018 after seven years on dialysis, but the organ failed after five years and he had resumed dialysis treatments.

The kidney was provided by eGenesis of Cambridge, Massachusetts, from a pig that had been genetically edited to remove genes harmful to a human recipient and add certain human genes to improve compatibility. The company also inactivated viruses inherent to pigs that have the potential to infect humans.

Kidneys from similarly edited pigs raised by eGenesis had successfully been transplanted into monkeys that were kept alive for an average of 176 days, and in one case for more than two years, researchers reported in October in the journal Nature.

Drugs used to help prevent rejection of the pig organ by the patient's immune system included an experimental antibody called tegoprubart, developed by Eledon Pharmaceuticals.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The surgery marks progress in xenotransplantation – the transplanting of organs or tissues from one species to another - said Dr. Robert Montgomery, director of the NYU Langone Transplant Institute, who was not involved in the case.

The field "is marching closer to becoming an alternative source of organs for the many hundreds of thousands suffering from kidney failure," he said in an email.

According to the United Network for Organ Sharing, more than 100,000 people in the U.S. await an organ for transplant, with kidneys in the greatest demand.

NYU surgeons had previously transplanted pig kidneys into brain-dead people.

Montgomery said transplant centers are taking different approaches in terms of gene edits and medications, adding that "another big step will be when the FDA authorizes clinical trials so we may better understand what will work best for patients on our waiting lists."

A University of Maryland team in January 2022 transplanted a genetically modified pig heart into a 57-year-old man with terminal heart disease, but he died two months later.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.